Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas. Show more
Location: Building 14, Stafford, TX, 77477, United States | Website: https://greenwichlifesciences.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
157.2M
52 Wk Range
$8.06 - $16.50
Previous Close
$11.53
Open
$11.62
Volume
36,501
Day Range
$10.87 - $11.68
Enterprise Value
154M
Cash
3.125M
Avg Qtr Burn
-2.126M
Insider Ownership
51.30%
Institutional Own.
10.45%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
GLSI-100 Details Breast cancer | Phase 3 Update |